Myriad Genetics (NASDAQ:MYGN) Issues Q4 2024 Earnings Guidance

Myriad Genetics (NASDAQ:MYGN) updated its fourth quarter 2024 earnings guidance on Wednesday. The company provided EPS guidance of 0.030-0.040 for the period, compared to the consensus EPS estimate of 0.030. The company issued revenue guidance of $209.0 million-$211.0 million, compared to the consensus revenue estimate of $212.8 million. Myriad Genetics also updated its FY 2025 guidance to 0.070-0.110 EPS.

Analyst Ratings Changes

A number of research firms recently weighed in on MYGN. StockNews.com raised shares of Myriad Genetics from a “hold” rating to a “buy” rating in a report on Thursday, January 9th. Leerink Partnrs lowered shares of Myriad Genetics from a “strong-buy” rating to a “hold” rating in a report on Monday, December 9th. Morgan Stanley decreased their target price on shares of Myriad Genetics from $32.00 to $21.00 and set an “equal weight” rating on the stock in a report on Monday, November 18th. UBS Group initiated coverage on shares of Myriad Genetics in a report on Tuesday, December 10th. They set a “neutral” rating and a $18.00 target price on the stock. Finally, Piper Sandler cut their price target on shares of Myriad Genetics from $30.00 to $24.00 and set a “neutral” rating for the company in a research note on Monday, November 11th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $24.27.

Myriad Genetics Stock Performance

MYGN opened at $13.87 on Wednesday. The company has a current ratio of 1.90, a quick ratio of 1.73 and a debt-to-equity ratio of 0.05. The company has a market cap of $1.26 billion, a price-to-earnings ratio of -10.67 and a beta of 1.89. The company’s 50 day moving average is $15.05 and its 200 day moving average is $22.17. Myriad Genetics has a 12-month low of $12.87 and a 12-month high of $29.30.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.